PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 215/42, A61K 31/47, C07D 221/16, 215/46, 417/12, 413/12

A1

(11) International Publication Number: WO 00/17165

(43) International Publication Date: 30 March 2000 (30.03.00)

(21) International Application Number: PCT/IB99/01534

(22) International Filing Date: 10 September 1999 (10.09.99)

(30) Priority Data:
60/100,927 17 September 1998 (17.09.98) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DENINNO, Michael, Paul [US/US]; 9 Hermitage Drive, Gales Ferry, CT 06335 (US). MAGNUS-ARYITEY, George, Tetteh [US/US]; 18 Meetinghouse Lane, Ledyard, CT 06339 (US). RUGGERI, Roger, Benjamin [US/US]; 53 Twin Lakes Drive, Waterford, CT 06385 (US). WESTER, Ronald, Thure [US/US]; 48 Seabury Avenue, Ledyard, CT 06339 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; c/o Simpson, Alison, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS



(I)

(57) Abstract

Cholesteryl ester transfer protein inhibitors, of the Formula (I), prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.